Lu Xiaojing, Lu Cuncun, Yang Yongjie, Shi Xiangfen, Wang Haibo, Yang Nan, Yang Kehu, Zhang Xiaojian
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Front Pharmacol. 2021 Apr 27;12:624534. doi: 10.3389/fphar.2021.624534. eCollection 2021.
Peptide receptor radionuclide therapy (PRRT) is an emerging therapeutic option for the treatment of neuroendocrine tumors (NETs), and the number of publications in this field has been increasing in recent years. The aim of the present study was to present the research status and summarize the key topics through bibliometric analysis of published PRRT literature. A literature search for PRRT research from 2000 to 2019 was conducted using the Science Citation Index Expanded of Web of Science Core Collection (limited to SCIE) on August 4, 2020. The VOSviewer, R-bibliometrix, and CiteSpace software were used to conduct the bibliometric analysis. From 2000 to 2019, a total of 681 publications (523 articles and 158 reviews) were retrieved. Annual publication outputs grew from three to 111 records. Germany had the largest number of publications, making the largest contribution to the field ( = 151, 22.17%). Active cooperation between countries/regions was observed. Kwekkeboom from the Erasmus Medical Center is perhaps a key researcher in the field of PRRT. The and ranked first for productive ( = 84, 12.33%) and co-cited ( = 3,438) journals, respectively. Important topics mainly included matters related to the efficacy of PRRT (e.g., Y-dotatoc and Lu-dotatate), the long-term adverse effects of PRRT (e.g., hematologic and renal toxicities), standardization of NETs and PRRT in practice, the development of medical imaging techniques, and the individual dose optimization of PRRT. Using bibliometric analysis, we gained deep insight into the global status and trends of studies investigating PRRT for the first time. The PRRT field is undergoing a period of rapid development, and our study provides a valuable reference for clinical researchers and practitioners.
肽受体放射性核素治疗（PRRT）是一种新兴的神经内分泌肿瘤（NETs）治疗选择，近年来该领域的出版物数量一直在增加。本研究的目的是通过对已发表的PRRT文献进行文献计量分析，呈现研究现状并总结关键主题。2020年8月4日，使用科学网核心合集的科学引文索引扩展版（仅限于SCIE）对2000年至2019年的PRRT研究进行了文献检索。使用VOSviewer、R-bibliometrix和CiteSpace软件进行文献计量分析。2000年至2019年，共检索到681篇出版物（523篇文章和158篇综述）。年出版物产量从3篇增长到111篇记录。德国的出版物数量最多，对该领域的贡献最大（n = 151，22.17%）。观察到国家/地区之间存在积极合作。伊拉斯谟医学中心的Kwekkeboom可能是PRRT领域的关键研究人员。《》和《》分别在高产期刊（n = 84，12.33%）和共被引期刊（n = 3438）中排名第一。重要主题主要包括与PRRT疗效相关的问题（例如，钇-奥曲肽和镥-奥曲肽）、PRRT的长期不良反应（例如，血液学和肾脏毒性）、NETs和PRRT在实践中的标准化、医学成像技术的发展以及PRRT的个体剂量优化。通过文献计量分析，我们首次深入了解了全球研究PRRT的现状和趋势。PRRT领域正在经历快速发展时期，我们的研究为临床研究人员和从业者提供了有价值的参考。
